Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Quizartinib in Moderate Hepatic Impairment
NCT04473664Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of quizartinib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Maximum Plasma Concentration at Day 22, Time to Maximum Plasma Concentration at Day 22 and 4 more. Started Sep 2020; status: completed.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04473664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04473664.